Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people ...

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...

Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

En una declaración reciente, el analista de Canaccord Genuity, Ed Nash, destacó los cambios dinámicos dentro del panorama de medicamentos para IgAN, mencionando la Aprobación Acelerada de la FDA para ...

As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are ...

As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...

NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia ™ (atrasentan), for the reduction of proteinuria ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Elme Communities is committed to elevating what home can be for middle-income renters by providing a higher level of quality, service, and experience. The Company is a multifamily real estate ...